Salah-Eddine Amini

Salah-Eddine Amini

Auto-generated profile, based on publicly available information

Salah-Eddine Amini

Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine University of Oslo Oslo Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2020 in Gut Microbes
Verified
Journal Article
Open access
THThomas Hueso
Thomas Hueso
KEKenneth Ekpe
Kenneth Ekpe
CMCamille Mayeur
Camille Mayeur
AGAnna Gatse
Anna Gatse
MJMarie Joncquel
Marie Joncquel
DSDavid Seguy
David Seguy
Induction chemotherapy (7 + 3 regimen) remains the gold standard for patients with acute myeloid leukemia (AML) but is responsible for gut damage leading to several complications such as bloodstream infection (BSI). We aimed to investigate the impact of induction chemotherapy on the intestinal barrier of patients with AML and in wild-type mice. Next, we assessed the potential benefit of strengthening the mucosal barrier in transgenic mice releasing a recombinant protein able to reinforce the mucus layer (Tg222). In patients, we observed a decrease of plasma citrulline, which is a marker of the functional enterocyte mass, of short-chain fatty acids and of fecal bacterial load, except for Escherichia coli and Enterococcus spp., which became dominant. Both the α and β-diversities of fecal microbiota decreased. In wild-type mice, citrulline levels decreased under chemotherapy along with an increase of E. coli and Enterococcus spp load associated with concomitant histologic impairment. By comparison with wild-type mice, Tg222 mice, 3 days after completing chemotherapy, had higher citrulline levels, a faster healing epithelium, and preserved α-diversity of their intestinal microbiota. This was associated with reduced bacterial translocations. Our results highlight the intestinal damage and the dysbiosis induced by the 7 + 3 regimen. As a proof of concept, our transgenic model suggests that strengthening the intestinal barrier is a promising approach to limit BSI and improve AML patients’ outcome.

27 April 2019 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
SASalah-Eddine Amini
Salah-Eddine Amini
VGValérie Gouyer
Valérie Gouyer
CPCéline Portal
Céline Portal
FGFrédéric Gottrand
Frédéric Gottrand
JDJean-Luc Desseyn
Jean-Luc Desseyn

25 July 2023 in The FASEB Journal
Verified
Journal Article
Open access
SASalah Edden Amini
Salah Edden Amini
SBSophie Emilie Bresson
Sophie Emilie Bresson
JRJerome Ruzzin
Jerome Ruzzin
Nr1i2 , a nuclear receptor known for its key function in xenobiotic detoxification, has emerged as a potential regulator of intestinal homeostasis and inflammation. However, the role of Nr1i2 in different intestinal segments remains poorly known. Moreover, in vivo investigations on intestinal Nr1i2 have essentially been performed in whole‐body Nr1i2 knockout ( Nr1i2 −/− ) mice where the deletion of Nr1i2 in all tissues may affect the intestinal phenotype. To better understand the role of Nr1i2 in the intestine, we generated intestinal epithelial‐specific Nr1i2 knockout (i Nr1i2 −/− ) mice and studied the duodenum, jejunum, ileum, and colon of these animals during steady‐state conditions and lipopolysaccharide (LPS)‐induced inflammation. As compared to control (i Nr1i2 +/+ ) mice, i Nr1i2 −/− mice showed normal intestinal permeability as assessed by in vivo FITC‐dextran test. The expression of genes involved in inflammation, tight‐ and adherens‐junction, proliferation, glucose, and lipid metabolism was comparable in the duodenum, jejunum, ileum, and colon of i Nr1i2 −/− and i Nr1i2 +/+ mice. In line with these findings, histological analyses of the jejunum revealed no difference between i Nr1i2 −/− and i Nr1i2 +/+ mice. When treated with LPS, the intestine of i Nr1i2 −/− mice had no increased inflammatory response as compared to i Nr1i2 +/+ mice. Moreover, the health monitoring of LPS‐treated i Nr1i2 −/− and i Nr1i2 +/+ mice was similar. Taken together, our results demonstrate that the specific deletion of Nr1i2 in the intestinal epithelium does not cause major intestinal damages in mice during both steady‐state and inflammatory conditions.

3 April 2026
Verified
Thesis
Closed access
SASalah Eddine Amini
Salah Eddine Amini
Le mucus est un gel viscoélastique complexe. Il est essentiel au maintien de l’intégrité des muqueuses et de leurs fonctions. Sa fraction organique est représentée principalement par les mucines gélifiantes (GFM). Seuls les modèles animaux génétiquement modifiés par recombinaison permettent l’étude du rôle des GFM en conditions physiologiques ou pathologiques dans un système parfaitement intégré.Nous avons utilisé ce type de modèles de souris transgéniques pour : 1- préciser l’expression et la localisation respective des deux principales GFM des cavités nasales, Muc5ac et Muc5b, à partir de souris Muc5b-GFP et Muc5b -/- ; 2- étudier les conséquences d’une chimiothérapie d’induction sur la barrière intestinale iléale et évaluer le bénéfice d’un mucus renforcé dans ce contexte grâce à des souris Tg222.Nos résultats montrent : 1-qu’en condition physiologique, Muc5ac qui est préférentiellement fucosylée, est produite dans l’épithélium respiratoire, alors que Muc5b qui est préférentiellement sialylée, est produite par les glandes de Bowman dans l’épithélium olfactif; 2- qu’après une chimiothérapie, un mucus renforcé ne permet pas de réduire les dommages initiaux de l’épithélium iléal qui sont aggravés par la présence du microbiote, mais qu’ensuite c’est l’interaction entre ce microbiote et le mucus qui permet une meilleure régénération de cet épithélium.Ces résultats soulignent le rôle essentiel qu’a le mucus dans l’interaction entre le microbiote et l’épithélium des muqueuses. Ils offrent des perspectives intéressantes de recherche dans la compréhension de l’atteinte de l’olfaction et l’atteinte intestinale chez les patients qui reçoivent une chimiothérapie.